FDA Approves Genentech’s Ocrevus (ocrelizumab) Shorter 2-Hour Infusion for Relapsing and Primary Progressive Multiple Sclerosis
If you are currently being treated with Ocrevus, ask your doctor about the shorter 2-hour Ocrevus infusion! If you would like more information on the new FDA approved 2-hour Ocrevus infusion please see below:
Click here for the official press release for the FDA Approval of the 2-hour Ocrevus infusion time!
